News

Your feedback is essential to shaping a user-friendly website that works better for everyone.

Recall reforms program update and preview of the PRAC Version 1.0.

Find out about new requirements for labels of injectable electrolyte medicines and updates to guidance for medicine sponsors.

We have introduced new features to improve your experience using Guidance on our website.

The TGA is updating information for nitrosamine impurities in medicines including acceptable intakes (AI).

TGA has made the decision not to register lecanemab (LEQEMBI) for the treatment of patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease and Mild Alzheimer's dementia (early Alzheimer's disease).